Comparing 2 biotech companies’ business models and the way they get financed: Funding rounds vs. Collaboration with pharma
Felice Verduyn-van Weegen has been with LSP since 2015, and is one of the Partners of the firm. LSP is the largest life sciences investor in Europe. Felice is part of the LSP investment team focused on private companies and is involved in all stages of the investment process. She has been involved in a large number of LSP’s investments and is at the moment a Board Director at AM-pharma, Amolyt therapeutics and Vico therapeutics. Prior to joining LSP, Felice was a consultant at McKinsey & Company where she worked on projects in the Netherlands and internationally with a prime focus on healthcare and technology. She has a scientific background in neuroscience and genetics, doing her research at VU Amsterdam and Harvard Medical School.